Results 191 to 200 of about 123,881 (268)

Association of Physical Activity With All‐Cause and CVD Mortality Across Metabolic and Obesity Phenotypes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To examine the independent and joint associations of metabolic status, obesity, and physical activity with all‐cause and cardiovascular disease (CVD) mortality across metabolic–obesity phenotypes. Materials and Methods We analysed 442 666 adults from the Korean National Health Insurance Service health screening cohort (2009–2012 ...
Yunmin Han, Younghwan Choi, Soomin Lee, Yeon Soo Kim   +3 more
wiley   +1 more source

Association between weight-adjusted waist index and cardiovascular disease: a systematic review and meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Pimenta K, Madondo E, Mukhopadhyay A, Patel J, Muhit S, Mzayek F, Bartelli D, Smeltzer M, Zhang H.   +8 more
europepmc   +1 more source

Higher Serum Testosterone Protects Against the Development of Type 2 Diabetes in Middle‐Aged but Not Older Men

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Low serum testosterone concentration has been reported to be causally linked to the risk of Type 2 diabetes (T2D). The benefit of T2D protection has been demonstrated to continue up to serum testosterone concentrations of 461 ng/dL (16 nmol/L).
Mahesh M. Umapathysivam, Andrew D. Vincent, Jason Tan, Alebachew Ashagre, David Jesudason, Gary Wittert   +5 more
wiley   +1 more source

Weight-adjusted-waist index as a mediator in the association between atherogenic index of plasma and obstructive sleep apnoea: insights from NHANES 2015-2020. [PDF]

J Health Popul Nutr
Liao L, Wang H, Tian F, Xiong Y, Wang L, Zhang Q, Jiang L, Xie Y.   +7 more
europepmc   +1 more source

Unveiling the BMI Risk Threshold for Osteoarthritis: Multi‐Database Causal and Nonlinear Evidence

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective To characterize the nonlinear relationship between BMI and osteoarthritis (OA), and to identify BMI thresholds that inform precise prevention strategies. Methods This multi‐database study integrated Global burden of disease 2021, National Health and Nutrition Examination Survey 2007–2018, and Genome‐Wide Association Studies.
Shaohong Yu, Li Zeng, Lei Yang, Yangjiang Ou, Chenglin Yang, Xiaoru Lin, Jingyi Shao, Qing Guan, Guobo Li, Xiuquan Lin   +9 more
wiley   +1 more source

Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Semaglutide, a GLP‐1 receptor agonist, has demonstrated significant weight loss benefits for patients with overweight or obesity in both oral and subcutaneous (s.c.) formulations. Given comparable systemic exposure between formulations, an indirect treatment comparison (ITC) was conducted to confirm comparable efficacy.
Molly Plotkin, Milana Ivkovic, Inger Smith, Naveen Rathor, Rohan Chowdhury, Alexander Hodkinson, Robert F. Kushner   +6 more
wiley   +1 more source

Association between weight-adjusted waist index and risk of mortality and disease progression in participants with chronic kidney disease: a prospective study from the UK Biobank. [PDF]

Front Nutr
Wu C, Pan C, Liu L, Li W.
europepmc   +1 more source

Rates of, Reasons for, and Reactions to Discontinuation of GLP‐1 Receptor Agonists: A Narrative Review

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT GLP‐1RAs are increasingly used for their glucose‐lowering and weight‐management effects, but many patients discontinue them. In this narrative review we aim to review real‐world, quantitative and qualitative GLP‐1RA discontinuation, adherence, and persistence evidence as it aligns with an established conceptual framework for understanding ...
Henry D. Heisey, L. Parker Gregg, Christopher D. Verrico, Dennis T. Villareal, Terri L. Fletcher   +4 more
wiley   +1 more source

Associations and predictive value of weight-adjusted waist index for cardiovascular outcomes in type 2 diabetes: evidence from the ACCORD study. [PDF]

Nutr J
Liu M, Pei J, Zeng C, Xin Y, Tang P, Hu X.   +5 more
europepmc   +1 more source

Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population‐Adjusted Indirect Treatment Comparison

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study aimed to indirectly compare the effects of oral semaglutide 25 mg versus orforglipron 36 mg on body weight loss, other cardiometabolic biomarkers, and tolerability in adults with overweight (body mass index [BMI] ≥ 27 kg/m2 and at least one obesity‐related complication) or obesity (BMI ≥ 30 kg/m2), without diabetes, using data ...
Wojciech Michalak, Martin Bøg, Theiss Bendixen, Rohan Chowdhury, Phoebe Cowley, Christian Laugesen, Naveen Rathor, Robert F. Kushner   +7 more
wiley   +1 more source